Published in Lancet on August 04, 1990
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) 3.88
Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood (2000) 3.45
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A (1985) 3.02
Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med (1984) 3.02
Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med (1995) 2.85
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood (2001) 2.52
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
Emergency ultrasound-based algorithms for diagnosing blunt abdominal trauma. Cochrane Database Syst Rev (2005) 2.28
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med (1987) 2.17
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01
Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis (1992) 1.98
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci U S A (2001) 1.90
Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol (1985) 1.86
Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer (1997) 1.85
Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it. Eur J Cancer (1997) 1.83
Mutations in the gene encoding neutrophil elastase (ELA2) are not sufficient to cause the phenotype of congenital neutropenia. Br J Haematol (2001) 1.78
Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med (1989) 1.67
Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer (1993) 1.63
Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J Immunol (1984) 1.54
Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood (2000) 1.54
Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis (2001) 1.53
Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med (1982) 1.50
Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45
In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood (1992) 1.44
Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol (1984) 1.44
Serum G-CSF levels are not increased in patients with antibody-induced neutropenia unless they are suffering from infectious diseases. Br J Haematol (1999) 1.39
Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med (1985) 1.37
[Evidence-based medicine and anaesthesiology--six steps towards implementation into clinical practice]. Anasthesiol Intensivmed Notfallmed Schmerzther (2003) 1.37
Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2. J Clin Immunol (1983) 1.36
Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev (2008) 1.35
Purified human interleukin-2 enhances induction of immune interferon. Cell Immunol (1983) 1.33
A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen (2003) 1.30
Chemotactic activity of recombinant human granulocyte colony-stimulating factor. Blood (1988) 1.30
Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood (1998) 1.27
Systematic review and meta-analysis of emergency ultrasonography for blunt abdominal trauma. Br J Surg (2001) 1.20
T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. Clin Immunol Immunopathol (1987) 1.19
OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells. J Immunol (1983) 1.19
[The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)]. Klin Padiatr (1981) 1.17
[Emergency ultrasound for blunt abdominal trauma--meta-analysis update 2003]. Zentralbl Chir (2003) 1.15
Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest (1985) 1.15
Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A (1986) 1.14
Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood (1989) 1.14
Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies. Blood (1983) 1.11
Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia (1997) 1.10
Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology (1986) 1.09
Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2. Cell Immunol (1984) 1.07
Lymphokine inducing "terminal differentiation" of the human monoblast leukemia line U937: a role for gamma interferon. Blood (1983) 1.06
Immunologic effects of interleukin 2 in primary immunodeficiency diseases. J Immunol (1983) 1.06
Practical aspects of quality-of-life measurement: design and feasibility study of the quality-of-life recorder and the standardized measurement of quality of life in an outpatient clinic. Cancer Treat Rev (1996) 1.05
Autologous and allogeneic mixed-lymphocyte responses following thermal injury in man: the immunomodulatory effects of interleukin 1, interleukin 2, and a prostaglandin inhibitor, WY-18251. Clin Immunol Immunopathol (1984) 1.04
Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate. J Clin Invest (1987) 1.04
Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia (1997) 1.04
Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood (2000) 1.03
Induction of T cell aggregation by antibody to a 16kd human leukocyte surface antigen. J Immunol (1984) 1.02
Differential effect of anti-beta 2-microglobulin on IL 2 production and IL 2 receptor expression in the primary mixed lymphocyte culture reaction. J Immunol (1985) 1.01
Purification and biochemical characterization of a human autocrine growth factor produced by Epstein-Barr virus-transformed B cells. J Immunol (1987) 1.01
Human interleukin 2: molecular biology, physiology and clinical possibilities. Immunobiology (1986) 1.00
Extramedullary hematopoiesis and intratumoral production of cytokines in childhood hepatoblastoma. Pediatr Res (1995) 0.98
Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics (2000) 0.98
Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci (2003) 0.97
Human endothelial cells regulate survival and proliferation of human mast cells. J Exp Med (2000) 0.97
Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2. Cell Immunol (1986) 0.97
Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J Immunol (1983) 0.96
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2000) 0.96
Human B cell-inducing factor(s) for production of IgM, IgG and IgA: independence from IL 2. J Immunol (1984) 0.95
The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol (1999) 0.95
Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol (1991) 0.95
High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest (1992) 0.93
Treatment of immunodeficiency with interleukin-2: initial exploration. J Biol Response Mod (1984) 0.93
Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia (2006) 0.93
Chromosomal aberrations in congenital bone marrow failure disorders--an early indicator for leukemogenesis? Ann Hematol (2007) 0.92
Parameters of self-organization in Hydra aggregates. Proc Natl Acad Sci U S A (2000) 0.92
Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood (1991) 0.92
Isotype profile and clinical relevance of anticardiolipin antibodies in Sjögren's syndrome. Ann Rheum Dis (1992) 0.91
Interleukin 2-dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies. J Immunol (1983) 0.91
Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia (2002) 0.91
Palliative radiotherapy in plasma cell myeloma. Radiother Oncol (1991) 0.90
Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia. Blood (1991) 0.90
Frequency of point mutations in the gene for the G-CSF receptor in patients with chronic neutropenia undergoing G-CSF therapy. Stem Cells (1997) 0.90
Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther (1996) 0.90
Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr (2001) 0.89
[Reversible germ cell toxicity following aggressive chemotherapy in patients with testicular tumors: results of a prospective study]. Klin Wochenschr (1989) 0.88
High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome). J Pediatr (1997) 0.88
Distinct differentiation-inducing activities of gamma-interferon and cytokine factors acting on the human promyelocytic leukemia cell line HL-60. Cancer Res (1985) 0.88
Antigen-induced human interferon-gamma production. Differential dependence on interleukin 2 and its receptor. J Immunol (1987) 0.88
Characterization of interleukin 2 (IL-2)-dependent cytotoxic T-cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL-2. Cell Immunol (1984) 0.88
Thrombopoietin induces the generation of distinct Stat1, Stat3, Stat5a and Stat5b homo- and heterodimeric complexes with different kinetics in human platelets. Exp Hematol (2000) 0.87
Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol (1987) 0.87
Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab (1994) 0.87